In a BMJ Group Blogs post, Caroline Robinson, global health advocacy manager for Results U.K., discusses the prevalence and treatment of tuberculosis (TB) and drug-resistant TB in Europe and provides the example of Romania. She writes, “[E]vidence brought to light in a new report [.pdf] released recently outlining the effect funding shortages will have on HIV and TB, including drug-resistant TB, in the European region suggests that Romania does not have the institutional capacity to ensure its citizens have the basic right to health. The country relies on grants from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which look set to end in 2013.” She continues, “[Global Fund] Board members should ensure that middle-income countries with epidemics among key populations can access critical Global Fund contributions and the E.U. and its member states must continue to provide the resources the fund requires to meet demand. Unless such support is given, countries like Romania will continue to fall further down the league tables in terms of treatment for this curable disease” (10/10).
“Zimbabwe is set to attain ‘universal’ coverage for AIDS treatment thanks in part to an $84 million disbursement [on Tuesday] by the United Nations-backed Global Fund to Fight AIDS, Tuberculosis and Malaria,” the U.N. News Centre reports (10/2). “The new disbursement will cover the cost of life-saving antiretroviral drugs (ARVs) for an additional 10,000 new patients, bringing the total number of people on treatment with Global Fund support to 203,440 by the end of the year,” the Global Fund announced in a press release. The funding also will support a six-month ARV buffer stock to prevent treatment interruptions for the 480,000 patients on therapy in Zimbabwe, the press release notes (10/2). The Global Fund’s announcement to support additional patients comes together with an announcement from PEPFAR to increase the number of patients supported by its program from 80,000 to 140,000, with a goal of having 160,000 patients on therapy by the end of next year, Zimbabwe’s Herald notes.
“Although no official decision has been announced about whether to continue the … Affordable Medicines Facility-Malaria (AMFm), many of those familiar with it have told Nature that it must change or be phased out after this year,” the magazine reports in an article examining the future of the pilot program that distributes malaria drugs in seven African countries. “The AMFm aims to make artemisinin-based combination therapies (ACTs) readily available and affordable in malaria-ridden countries by relying on the free market for their distribution,” but “it is unclear how many of the drugs reached the pilot program’s target populations,” Nature writes. The magazine describes possible options for the program, and notes the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will recommend a future path for the program at its meeting next month (Maxmen, 10/2).
In an article on the International HIV/AIDS Alliance’s webpage, the organization compares a new funding model adopted by the Global Fund to Fight AIDS, Tuberculosis and Malaria to its own “key principles” and “outline[s] how civil society is involved in refining the process of how money will be allocated.” The article addresses key elements of the new model as well as next steps leading up to the next Global Fund Board meeting in November (10/1).
IRIN reports on allegations that a grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria to Uganda was misused. “Evidence of the mismanagement of a $51 million malaria grant to Uganda from the Global Fund resulted in the July arrest of three Ministry of Health employees and prompted a police investigation into the matter,” the news service writes, adding, “In September, the organization called for the refund of any ineligible expenses under the grant and the strengthening of safeguards to prevent future misappropriation of funds.”
On its website, the International HIV/AIDS Alliance describes a new publication, titled “Of Spices and Silk: Sharing Stories of Technical Support to Global Fund Grants in Asia,” which presents 11 case stories showing how the Alliance’s regional Technical Support Hubs have provided assistance to Global Fund grant recipients (9/27). “The case stories were written during a writeshop held in Bangkok in August 2012 where participants were invited to use a narrative structure to reflect on and draw out their experiences working as consultants providing technical support for Global Fund grants,” the report homepage states (9/25).
Secretary of State Hillary Clinton reflects on changes in U.S. global health diplomacy since taking office in this Global Health and Diplomacy opinion piece. “America had been leading the global health fight for decades,” but “we recognized that to sustain the impact of our work, we needed to change the way we did business,” she writes. “For example, while our agencies were providing tremendous leadership in isolation, they could still do more to collaborate effectively,” she writes, adding, “[W]e weren’t doing enough to coordinate our efforts with other donors or our partner countries,” and “we weren’t building sustainable systems to eventually allow our partner countries to manage more of their own health needs.” She says, “We were unintentionally putting a ceiling on the number of lives we could save.”
“The Global Fund to Fight AIDS, Tuberculosis and Malaria has released initial details on its new funding model, … [b]ut as the fund works to finalize the model before next year, civil society is criticizing the process for being untransparent and rushed,” IRIN reports in an article examining the draft model and reaction to it. Some groups have expressed concern over the fund’s decision to “base funding allocations for each diseases on previously used levels for up to one year,” while “many African civil society organizations have expressed dissatisfaction with the speed and transparency of the process,” IRIN writes. “The Global Fund board is expected to make a final decision on the model at its November board meeting,” the news service notes (9/25).
The Coca-Cola Company and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the expansion of a pilot project, called “Project Last Mile,” that uses Coca Cola’s “‘expansive global distribution system and core business expertise’ to help deliver critical medicines to remote parts of the world, beginning in rural Africa,” Pharma Times reports. “The public-private partnership was established in 2010 to help Tanzania’s government-run medicine distribution network, Medical Stores Department, build a more efficient supply chain by using Coca-Cola’s” delivery system model, the news service writes, adding, “The latest phase of the partnership, developed in cooperation with the likes of the Bill & Melinda Gates Foundation, Accenture and Yale University, will increase the availability of critical medicines to 75 percent of Tanzania and expand the initiative to Ghana and Mozambique” (Grogan, 9/26).
Forbes features an interview with Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, in which she “discusse[s] her motivations for pursuing a career in international affairs and social change, her experience as a senior program officer at the [Bill & Melinda Gates Foundation], what lessons she learned during her time at Gates that are most applicable in her new executive role at Friends of the Global Fight, the current landscape of challenges and solutions, and the role of technology in accelerating progress.” In the interview, Derrick said, “The mobilization to defeat these diseases in the past decade has been stunningly successful. … But there is so much more that needs to be done. If we don’t muster the resources to keep up the fight, and all commit to doing our part in a time of constrained resources, we risk backsliding on the progress we’ve already invested in” (Kanani, 9/21).